Literature DB >> 35502546

Establishment of the LNCaP Cell Line - The Dawn of an Era for Prostate Cancer Research.

Cory Abate-Shen1,2,3,4, Francisca Nunes de Almeida1.   

Abstract

Among the relatively few established human prostate cancer cell lines, LNCaP cells are unique in their ability to model key stages of prostate cancer progression. Analyses of LNCaP cells and their derivatives have been invaluable for elucidating important translational aspects of prostate tumorigenesis, metastasis, and drug response, particularly in the context of androgen receptor signaling. Here, we present major highlights from a wealth of literature that has exploited LNCaP cells and their derivatives to inform on prostate cancer progression and androgen response for improving the treatment of patients with prostate cancer. See related article by Horoszewicz and colleagues, Cancer Res 1983;43:1809-18. ©2022 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35502546      PMCID: PMC9153264          DOI: 10.1158/0008-5472.CAN-22-1065

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   13.312


  3 in total

1.  Transdifferentiation of cultured human prostate cancer cells to a neuroendocrine cell phenotype in a hormone-depleted medium.

Authors:  R Shen; T Dorai; M Szaboles; A E Katz; C A Olsson; R Buttyan
Journal:  Urol Oncol       Date:  1997 Mar-Apr       Impact factor: 3.498

2.  LNCaP model of human prostatic carcinoma.

Authors:  J S Horoszewicz; S S Leong; E Kawinski; J P Karr; H Rosenthal; T M Chu; E A Mirand; G P Murphy
Journal:  Cancer Res       Date:  1983-04       Impact factor: 12.701

3.  NKX3.1 Localization to Mitochondria Suppresses Prostate Cancer Initiation.

Authors:  Alexandros Papachristodoulou; Aditya Dutta; Antonio Rodriguez-Calero; Sukanya Panja; Elizabeth Margolskee; Renu K Virk; Teresa A Milner; Luis Pina Martina; Jaime Y Kim; Matteo Di Bernardo; Alanna B Williams; Elvis A Maliza; Joseph M Caputo; Christopher Haas; Vinson Wang; Guarionex Joel De Castro; Sven Wenske; Hanina Hibshoosh; James M McKiernan; Michael M Shen; Mark A Rubin; Antonina Mitrofanova; Cory Abate-Shen
Journal:  Cancer Discov       Date:  2021-04-23       Impact factor: 39.397

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.